Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maralixibat in Intrahepatic Cholestasis of Pregnancy (OASIS)
NCT07823127Phase 2Not yet recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2027
- Primary completion
- Jan 2029
01
Overview
Phase 2, open-label, single-arm trial of maralixibat in intrahepatic cholestasis of pregnancy (ICP), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
maralixibat
03
Conditions
intrahepatic cholestasis of pregnancy (ICP)
Beyond the preview
Go deeper on NCT07823127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823127.